Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Benzer Materyaller

• EGFR activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity
  Yazar:: Pfäffle, Heike N., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  Yazar:: Khandekar, Melin J., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
  Yazar:: Piotrowska, Zofia, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period
  Yazar:: McClatchy, David M., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
  Yazar:: Niederst, Matthew J., ve diğerleri
  Baskı/Yayın Bilgisi: (2015)